Arcutis Q4 revenue rises 84% on ZORYVE sales, raises FY guidance

Arcutis Biotherapeutics

25/02/2026 21:12

Overview

Biopharmaceutical firm's Q4 2025 net product revenue rose 84% yr/yr, driven by ZORYVE sales

Company achieved positive operating cash flow in Q4 2025

Raised 2026 full-year net product sales guidance to $480 mln – $495 mln

Outlook

Company raised 2026 full-year net product sales guidance to $480 mln – $495 mln

Company anticipates maintaining positive operating cash flow quarterly going forward

Arcutis plans sNDA submission for ZORYVE cream in Q2 2026

Result Drivers

DEMAND FOR ZORYVE - Strong demand for ZORYVE drove 84% year-over-year increase in Q4 net product revenue

SALES FORCE EXPANSION - Co expanded dermatology sales force to optimize prescriber targeting and deepen ZORYVE adoption

Company press release: ID:nGNX4YZCxf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$127.50 mln
Q4 Net Income
$17.40 mln
Q4 Operating Expenses
$111.12 mln
Q4 Operating Income
$18.39 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $31.00, about 14.9% above its February 24 closing price of $26.98

The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 95 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)